Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

British journal of clinical pharmacology - 1 Sept 2007

Zhang Wei, Chen Bi-Lian, Ozdemir Vural, He Yi-Jing, Zhou Gan, Peng Dao-Di, Deng Sheng, Xie Qi-Ying, Xie Wei, Xu Lin-Yong, Wang Lian-Ci, Fan Lan, Wang An, Zhou Hong-Hao

Abstract excerpt

AIMS: Pravastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is widely used both in primary and secondary prevention of coronary heart disease (CHD). Pravastatin is not subject to metabolism by cytochrome P450s, but it is actively transported from blood into target tissues (e.g. hepatocytes in the liver) by the organic anion transporting polypeptide 1B1 (OATP1B1), encoded by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Disease

Share to Lipids

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Pravastatin

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 17439540
DOI: 10.1111/j.1365-2125.2007.02892.x
PMCID: PMC2000640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.PMID 17439540Read ↗

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.Semantic proximity Read ↗

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.Semantic proximity Read ↗

Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.Semantic proximity Read ↗

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.Semantic proximity Read ↗

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.Semantic proximity Read ↗

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.Semantic proximity Read ↗

Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.Semantic proximity Read ↗

The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.Semantic proximity Read ↗

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.Semantic proximity Read ↗

SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in South Indian coronary artery disease patients.Semantic proximity Read ↗

Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.Semantic proximity Read ↗

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.